BOLD is expected to report earnings to rise 35.00% to -81 cents per share on August 17
Q2'26
Est.
$-0.81
Q1'26
Beat
by $0.20
Q4'25
Beat
by $0.58
Q3'25
Beat
by $0.47
Q2'25
Beat
by $0.32
The last earnings report on May 08 showed earnings per share of -60 cents, beating the estimate of -80 cents. With 29.77M shares outstanding, the current market capitalization sits at 31.45M.
A.I. Advisor
published General Information
General Information
a developer of gene therapy products for patients with serious rare diseases
A.I.dvisor indicates that over the last year, BOLD has been loosely correlated with TVTX. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if BOLD jumps, then TVTX could also see price increases.
BOLD's Stochastic Oscillator dives into oversold zone
The Stochastic Oscillator for BOLD moved into oversold territory on June 22, 2026. Be on the watch for the price uptrend or consolidation in the future. At that time, consider buying the stock or exploring call options.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BOLD advanced for three days, in of 88 cases, the price rose further within the following month. The odds of a continued upward trend are .
BOLD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on June 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BOLD as a result. In of 35 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
BOLD moved below its 50-day moving average on June 09, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for BOLD crossed bearishly below the 50-day moving average on June 11, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 6 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BOLD declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for BOLD entered a downward trend on June 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.364) is normal, around the industry mean (20.966). P/E Ratio (0.156) is within average values for comparable stocks, (36.007). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.690). BOLD has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (0.000) is also within normal values, averaging (367.026).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. BOLD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BOLD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Boundless Bio (BOLD) stock Forecast, Price Targets and Analysts Predictions - Tickeron.com
